RxDoctor Payments DataLook up a doctor →

Freddy Espinoza

Family · Fresno, CANPI 1124440524

Payments from drug & device makers

$33,408in general payments, 2019–2025

Across 921 payments — averaging $36.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$8K
  • Novo Nordisk$3K
  • Lilly USA, LLC$3K
  • Amgen$3K
  • AstraZeneca$2K
  • Abbott$1K
  • plus $13K from 51 others

What the payments were for

  • Consulting fees$5952%
  • Speaking & faculty fees$6,77520%
  • Food & beverage$25,92678%
  • Education$530%
  • Gifts$590%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,408 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$69,310
Medicare patients
182
Services billed
893

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide328$469,786
JardianceEmpagliflozin123$180,742
RybelsusSemaglutide60$94,274
MounjaroTirzepatide70$73,969
FarxigaDapagliflozin Propanediol43$59,899
XyostedTestosterone Enanthate36$25,403
TrulicityDulaglutide17$22,356
Cinacalcet Hcl11$15,167
Gvoke Hypopen 2-PackGlucagon23$13,304
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog31$12,976
Fiasp FlextouchInsulin Aspart (Niacinamide)20$9,693
Gvoke Hypopen 1-PackGlucagon21$8,508
Tresiba Flextouch U-100Insulin Degludec18$7,119
Novolog FlexpenInsulin Aspart28$6,056
Humalog Kwikpen U-100Insulin Lispro20$4,394

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$3,488$564,060388 claims
Boehringer IngelheimJardiance$1,072$180,742123 claims
Lilly USA, LLCMounjaro, Trulicity$2,844$96,32487 claims
AstraZenecaFarxiga$2,031$59,89943 claims
Antares Pharma, Inc.Xyosted$709$25,40336 claims
AbbVieSynthroid$676$1,93816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.

Other family in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →